Archive | Clinical Trials

Sotigalimab/Pembrolizumab Jumpstarts Immune Activity, Ignites Clinical Responses in Metastatic Melanoma

Treatment with the CD40 agonist sotigalimab (APX005M) in addition to pembrolizumab (Keytruda) elicited immunologic changes that yielded positive clinical responses in patients with unresectable stage III or IV metastatic melanoma, according to phase 1/2 findings (NCT02706353) presented during the 2022 AACR Annual Meeting.

Read the full story

Posted in Melanoma News, Health Professionals, Clinical Trials

Evaxion Biotech Adopts Personalis Immune Profiling Platform for Melanoma Immunotherapy Trial

NEW YORK – Personalized cancer therapy firm Evaxion Biotech and cancer genomics firm Personalis said on Tuesday that they will use Personalis’ immune profiling platform in a Phase IIb trial evaluating the efficacy and safety of Evaxion’s neoepitope-targeting therapy EVX-01, in combination with Merck’s Keytruda (pembrolizumab), for advanced melanoma patients.

Read the full story

Posted in Melanoma News, Health Professionals, Clinical Trials

RELATIVITY-047 Update: Novel Immunotherapy Duo Delays Disease Progression in Advanced Melanoma

A novel immunotherapeutic combination that targets PD-1 and the LAG-3 pathway significantly delayed disease progression as a first-line treatment of advanced or unresectable melanoma.

Read the full story

Posted in Melanoma News, Health Professionals, Clinical Trials

Phio Pharma initiates Phase Ib trial of melanoma treatment

Phio Pharmaceuticals has initiated subject enrolment in the Phase Ib clinical trial of its lead programme, PH-762, to treat advanced melanoma.

Read the full story

Posted in Melanoma News, Health Professionals, Clinical Trials